Optimizing therapeutic antibody function: progress with Fc domain engineering.
about
Role of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibodyBiological evaluation of 131I- and CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors.Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.Etanercept biosimilarsEngineered antibody variable and constant domains as therapeutic candidates.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.CF750-A33scFv-Fc-Based Optical Imaging of Subcutaneous and Orthotopic Xenografts of GPA33-Positive Colorectal Cancer in Mice.Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Production of α2,6-sialylated IgG1 in CHO cellsAbsorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.Stabilizing the CH2 Domain of an Antibody by Engineering in an Enhanced Aromatic SequonUsing antibodies to target cancer therapeutics.Side effects of cytokines approved for therapy.Nebulization as a delivery method for mAbs in respiratory diseases.Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.Production and characterization of a CD25-specific scFv-Fc antibody secreted from Pichia pastoris.Molecular and functional analysis of monoclonal antibodies in support of biologics development.Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology.Highly covarying residues have a functional role in antibody constant domains.
P2860
Q27681993-19F1BCD2-D983-4EF1-8FB8-A3C2FEB2E8A8Q33597766-858C95F9-63C1-425C-AB95-CB48DC27FA36Q34545655-8403B8B4-46EC-409A-A54B-9DA379AC8535Q35020358-238A07A8-2674-4B97-A35F-1AD1275A5A00Q35044156-544DF836-9933-493E-897D-DEE9B593310AQ35569418-BA91D656-CF9D-4C77-8702-FDCE2FFE8941Q35680685-BBADE9B7-C5BC-4C0F-AA0E-3890DDB94FEFQ35857869-44EA1584-0E6E-4763-9CAA-8311756434BAQ35929084-3BDA8431-37B0-4D4B-8421-B93802965B3BQ36213335-30189F61-7A38-44C7-82FC-BD390E552411Q36331552-A5584C0C-4D8D-4D46-88C0-B4D6DF14AF0AQ36855617-E57830A0-03D9-49F4-B79A-0B6A385DF906Q38014920-69E730DE-CE90-4B7E-9A07-669173E394EBQ38255698-D3C7575A-B7FE-480D-A360-0617CB6F66B9Q38306677-43F63B3C-7688-4613-A24B-5679B6A3ABA8Q38808291-18849B74-6FB3-4DB6-80C3-5C7FF6630CB1Q39224359-00B00C2D-3F09-4430-8DEB-E2A0120E9C2DQ39451572-51910E32-0573-4A9A-B395-9F960FD6423AQ41831737-687D322D-7E95-4635-9CAC-CB87DEDA9E5FQ44243757-12B61340-8C66-474E-A526-6E78968FB7AE
P2860
Optimizing therapeutic antibody function: progress with Fc domain engineering.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@en
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@nl
type
label
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@en
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@nl
prefLabel
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@en
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@nl
P2860
P1433
P1476
Optimizing therapeutic antibody function: progress with Fc domain engineering.
@en
P2093
Etsuji Kaneko
Rinpei Niwa
P2860
P356
10.2165/11537830-000000000-00000
P577
2011-02-01T00:00:00Z
P6179
1036760841